Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA217820

Local Sample ID:	B01-01_60_1_1703
Subject ID:	SU002359
Subject Type:	Cultured cells
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Gender:	Not applicable
Cell Biosource Or Supplier:	Sigma-Aldrich (St. Louis, MO)
Cell Strain Details:	Hep3B

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002371
Treatment Summary:	Generation of resistant Hep3B cell line: Resistant Hep3B cells were developed in clinically relevant models. In T-75 flasks, Hep3B cells were seeded overnight and incubated at 37°C. The cells were then treated with sorafenib at the 10 % inhibitory concentration (IC10) (0.4µM) of sorafenib (Biovision, Milpitas, CA, USA #BAY 43-9006) to mimic the clinically consumed low dose of chemotherapeutic drugs by a cancer patient who is then exposed to escalating doses over time. To develop resistance, the survived cells were transplanted to a new flask and then treated with sorafenib at escalating concentrations over six months. Then, sorafenib at concentration IC10 (0.4µM) was persistently retained in the culture media to ensure and maintain resistance. MTT cell viability assay was performed each month to validate the resistance behavior of the cells.

Treatment ID:

TR002371

Treatment Summary:

Generation of resistant Hep3B cell line: Resistant Hep3B cells were developed in clinically relevant models. In T-75 flasks, Hep3B cells were seeded overnight and incubated at 37°C. The cells were then treated with sorafenib at the 10 % inhibitory concentration (IC10) (0.4µM) of sorafenib (Biovision, Milpitas, CA, USA #BAY 43-9006) to mimic the clinically consumed low dose of chemotherapeutic drugs by a cancer patient who is then exposed to escalating doses over time. To develop resistance, the survived cells were transplanted to a new flask and then treated with sorafenib at escalating concentrations over six months. Then, sorafenib at concentration IC10 (0.4µM) was persistently retained in the culture media to ensure and maintain resistance. MTT cell viability assay was performed each month to validate the resistance behavior of the cells.